한국임상수의학회지 (Journal of Veterinary Clinics)

  • 제36권1호
  • /
  • Pages.30-37
  • /
  • 2019
  • /
  • 1598-298X(pISSN)
  • /
  • 2384-0749(eISSN)
한국임상수의학회 (The Korean Society of Veterinary Clinics)
권호 표지
DOI QR코드

DOI QR Code

A Study of Gastrointestinal and Bone Marrow Adverse Events after Administration of Various Chemotherapeutic Agents in Canine Malignant Tumor Patients

  • Ji, Na-Ni (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Song, Joong-Hyun (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Hwang, Tae-Sung (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Lee, Hee-Chun (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Yu, Do-Hyeon (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Jung, Dong-In (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University)
  • 투고 : 2018.03.20
  • 심사 : 2019.01.25
  • 발행 : 2019.02.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The purpose of this present study was to objectively evaluate gastrointestinal and bone marrow AEs after administration of various chemotherapeutic agents in canines with malignant tumors, using the Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE), which includes descriptive terminology used for adverse events (AEs) reported in dogs and cats. The medical records of 42 dogs with malignant tumor that underwent chemotherapy were reviewed retrospectively. There were no significant differences in the prevalence of gastrointestinal AEs among the 5 chemotherapeutic agents (vincristine, cyclophosphamide, doxorubicin, lomistine, and carboplatin). The prevalence of bone marrow AEs was significantly higher after administration of lomustine than after administration of vincristine or doxorubicin. Grade 1 AEs of the gastrointestinal tract and bone marrow were most often observed after administration of various chemotherapeutic agents. Delayed and cumulative myelosuppression of lomustine in some dogs receiving regular blood examination were identified. The findings of this study will help predict possible gastrointestinal and bone marrow AEs due to the use of chemotherapeutic agents to treat canines with malignant tumors.

키워드

참고문헌

  1. Blachley JD, Hill JB. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 1981; 95: 628-632. https://doi.org/10.7326/0003-4819-95-5-628
  2. Bregazzi VS, LaRue SM, McNiel E, Macy DW, Dernell WS, Powers BE, Withrow SJ. Treatment with a combination of doxorubicin, surgery, and radiation versus surgery and radiation alone for cats with vaccine-associated sarcomas: 25 cases (1995-2000). J Am Vet Med Assoc 2001; 218: 547-550. https://doi.org/10.2460/javma.2001.218.547
  3. Chun R, Garrett L, Vail D. Cancer Chemotherapy. In: Small Animal Clinical Oncology, 4 th ed. St. Louis: Saunders Elsevier. 2007: 163-192.
  4. Chun R, Knapp DW, Widmer WR, DelNicola DB, Glickman NW, Kuczek T, Degortari A, Han CM. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997; 11: 279-283. https://doi.org/10.1111/j.1939-1676.1997.tb00465.x
  5. Dennison JB, Jones DR, Renbarger JL, Hall SD. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 2007; 321: 553-563. https://doi.org/10.1124/jpet.106.118471
  6. Eschalier A, Lavarenne J, Burtin C, Renoux M, Chapuy E, Rodriguez M. Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 1988; 21: 246-250. https://doi.org/10.1007/BF00262779
  7. Fan TM, Kitchell BE, Dhaliwal RS, Jones PD, Hintermeister JG, Paria BC. Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: critical assessment of a practical dosing regimen. J Am Anim Hosp Assoc 2002; 38: 357-363. https://doi.org/10.5326/0380357
  8. Hammer AS, Couto CG, Filppi J, Getzy D, Shank K. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med 1991; 5: 160-166. https://doi.org/10.1111/j.1939-1676.1991.tb00943.x
  9. Heading K, Brockley L, Bennett P. CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07). Aust Vet J 2011; 89: 109-116. https://doi.org/10.1111/j.1751-0813.2011.00690.x
  10. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl Med 2008; 358: 2482-2494. https://doi.org/10.1056/NEJMra0706547
  11. Kristal O, Rassnick KM, Gliatto JM, Northrup NC, Chretin JD, Morrison-Collister K, Cotter SM, Moore AS. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. J Vet Intern Med 2004; 18: 75-80. https://doi.org/10.1111/j.1939-1676.2004.tb00138.x
  12. Lori J, Stein T, Thamm D. Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebocontrolled study. Vet Comp Oncol 2010; 8: 188-195. https://doi.org/10.1111/j.1476-5829.2010.00215.x
  13. MacDonald V. Chemotherapy: managing side effects and safe handling. Can Vet J 2009; 50: 665.
  14. McKnight JA. Principles of chemotherapy. Clin Tech Small Anim Pract 2003; 18: 67-72. https://doi.org/10.1053/svms.2003.36617
  15. Moore AS, London CA, Wood CA, Williams LE, Cotter SM, L'Heureux DA, Frimberger AE. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J Vet Intern Med 1999; 13: 395-398. https://doi.org/10.1111/j.1939-1676.1999.tb01452.x
  16. Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 1998; 16: 121-128. https://doi.org/10.1023/A:1006088907271
  17. O'Keefe DA, Sisson DD, Gelberg HB, Schaeffer DJ, Krawiec DR. Systemic toxicity associated with doxorubicin administration in cats. J Vet Intern Med 1993; 7: 309-317. https://doi.org/10.1111/j.1939-1676.1993.tb01024.x
  18. Rassnick KM, Gieger TL, Williams LE, Ruslander DM, Northrup NC, Kristal O, Myers NC, Moore AS. Phase I evaluation of CCNU (Lomustine) in tumor-bearing cats. J Vet Intern Med 2001; 15: 196-199. https://doi.org/10.1111/j.1939-1676.2001.tb02311.x
  19. Rassnick KM, Ruslander DM, Cotter SM, Al-Sarraf R, Bruyette DS, Gamblin RM, Meleo KA, Moore AS. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc 2001; 218: 1444-1448. https://doi.org/10.2460/javma.2001.218.1444
  20. Rau S, Barber L, Burgess K. Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs. J Vet Intern Med 2010; 24: 1452-1457. https://doi.org/10.1111/j.1939-1676.2010.0611.x
  21. Vail DM. Supporting the veterinary cancer patient on chemotherapy: neutropenia and gastrointestinal toxicity. Top Companion Anim Med 2009; 24: 122-129. https://doi.org/10.1053/j.tcam.2009.02.004
  22. Vale D. Veterinary co-operative oncology group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats. Vet Comp Oncol 2004; 2: 194-213. https://doi.org/10.1111/j.1476-5810.2004.0053a.x
  23. Victor A, Tilt N, Rowan TG, Clemence RG. Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. Am J Vet Res 2007; 68: 48-56. https://doi.org/10.2460/ajvr.68.1.48
  24. Weiss RB, Issell BF. The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). Cancer Treat Rev 1982; 9: 313-330. https://doi.org/10.1016/S0305-7372(82)80043-1
  25. Williams LE, Rassnick KM, Power HT, Lana SE, Morrison- Collister KE, Hansen K, Johnson JL. CCNU in the treatment of canine epitheliotropic lymphoma. J Vet Intern Med 2006; 20: 136-143. https://doi.org/10.1111/j.1939-1676.2006.tb02833.x